Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition